MBT-2 Xenograft Model Service for Bladder Cancer

The MBT-2 Xenograft Model Service for Bladder Cancer provides a robust, chemically induced murine transitional cell carcinoma platform essential for evaluating novel therapeutic strategies in preclinical oncology research. Alfa Cytology leverages this well-established syngeneic model to deliver comprehensive preclinical evaluation services, enabling researchers to accelerate bladder cancer drug discovery with reliable, reproducible tumor data generated under stringent quality standards.

Overview of MBT-2 Xenograft Model for Bladder Cancer

The MBT-2 (Mouse Bladder Tumor-2) cell line was originally established from a FANFT (N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide) chemically induced bladder tumor in C3H/He mice, representing one of the most extensively characterized murine transitional cell carcinoma models in bladder cancer research. As a chemically induced model, MBT-2 faithfully recapitulates the etiology of human bladder cancer, where chemical carcinogenesis remains a predominant risk factor. The cell line exhibits an epithelial morphology with polygonal cells forming multilayered colonies in vitro, and demonstrates a highly tumorigenic and metastatic phenotype when implanted in immunocompetent syngeneic hosts. Genetically, MBT-2 cells harbor characteristic mutations including activated Hras (G12V) and alterations in Trp53, alongside a polyploid karyotype ranging from 4N to 16N, closely mirroring the genomic instability observed in human muscle-invasive bladder cancer.

In xenograft applications, MBT-2 tumors can be established through both subcutaneous and orthotopic implantation routes, with subcutaneous models offering straightforward tumor monitoring and orthotopic models providing a microenvironment that more closely mimics natural disease progression. The model has been widely employed to evaluate radiation sensitization, immune checkpoint inhibitor combinations, intravesical therapies, and novel small molecule inhibitors. Notably, MBT-2 cells maintain expression of transitional cell markers including cytokeratins and uroplakins, while upregulating pro-angiogenic factors such as VEGF and MMP-9, making this model particularly valuable for studying tumor invasion, metastasis, and therapeutic response in an immunocompetent setting where host immune-tumor interactions can be fully assessed.

Figure 1. The anti-tumor effect of intratumoral xenogeneic urothelial cells in monotherapy and combination with chemotherapy using two murine bladder heterotopic graft tumor models. (Huang, Chi-Ping, et al., 2023)

Cell Line Information: MBT-2

The following table summarizes the key characteristics and specifications of the MBT-2 cell line widely used in bladder cancer preclinical research:

Our Services

Alfa Cytology offers a comprehensive MBT-2 Xenograft Model Service tailored to accelerate your bladder cancer therapeutic pipeline. Our preclinical platform encompasses tumor establishment, longitudinal monitoring, treatment administration, and multi-parameter endpoint analysis, all conducted under rigorous quality management protocols to ensure data integrity and reproducibility for your IND-enabling studies.

Workflow of MBT-2 Xenograft Model Construction

The construction of the MBT-2 xenograft model follows a standardized, multi-step protocol designed to ensure consistent tumor establishment and reliable therapeutic evaluation. The workflow integrates cell preparation, animal handling, tumor inoculation, monitoring, and endpoint analysis, with flexibility to accommodate both subcutaneous and orthotopic implantation strategies based on study objectives.

1. Cell Preparation and Quality Control: MBT-2 cells are thawed from cryopreserved stocks and expanded under standard culture conditions (37 degrees C, 5% CO2). Prior to implantation, cells undergo comprehensive quality control testing including viability assessment, mycoplasma screening, and authentication verification to ensure optimal tumorigenic potential and experimental reproducibility.
2. Animal Selection and Acclimatization: Syngeneic C3H/HeN or C3H/HeJ mice (typically 6-8 weeks old) are selected based on study design requirements. Animals are acclimatized to the facility environment for a minimum of 5-7 days, with health monitoring conducted daily to establish baseline physiological parameters and ensure suitability for experimental procedures.
3. Tumor Cell Inoculation: For subcutaneous models, a cell suspension of 1x10^6 to 5x10^6 viable MBT-2 cells in PBS or serum-free medium is injected into the flank or hind leg using a sterile insulin syringe. For orthotopic models, cells are instilled intravesically via a 22-gauge urethral catheter following gentle bladder preconditioning to enhance tumor cell adherence to the urothelial mucosa.
4. Tumor Monitoring and Measurement: Subcutaneous tumors are monitored via caliper measurements every 2-3 days beginning from Day 7 post-implantation, with tumor volume calculated using the modified ellipsoid formula (length x width^2 x 0.5). Orthotopic tumors are monitored through non-invasive imaging modalities such as bioluminescence imaging (BLI), MRI, or ultrasound to track tumor progression without sacrificing animals prematurely.
5. Treatment Administration: Upon reaching the target tumor volume (typically 100-200 mm^3 for subcutaneous models), animals are randomized into treatment and control cohorts. Test compounds are administered according to predefined dosing regimens (oral gavage, intraperitoneal, intravenous, or intravesical), with dosing volume and frequency optimized based on compound pharmacokinetic properties and study endpoints.
6. Endpoint Analysis and Sample Collection: At study termination, animals are humanely euthanized and tumors are excised for comprehensive analysis. Endpoints include tumor weight and volume, histopathological evaluation (H&E staining), immunohistochemistry for target protein expression, flow cytometry for immune infiltrate characterization, and molecular profiling (Western blot, qPCR, RNA-seq) to elucidate treatment mechanisms.

Figure 2. MBT-2 xenograft model construction workflow.

Case Study-MBT-2 Xenograft Model Development

Alfa Cytology has successfully established and validated the MBT-2 xenograft model across multiple preclinical studies evaluating diverse therapeutic modalities including radiation sensitization, immune checkpoint inhibitor combinations, and novel intravesical agents. Our internal datasets demonstrate consistent tumor take rates exceeding 90% with predictable growth kinetics, enabling robust statistical powering for treatment efficacy assessments. Detailed case study data including tumor growth curves, survival analyses, histopathological findings, and biomarker profiling results are available upon request for client evaluation and study planning purposes.

Why Choose Alfa Cytology?

Alfa Cytology stands out as a trusted preclinical CRO partner for bladder cancer research, offering specialized expertise in MBT-2 xenograft model development and execution. Our integrated service platform combines scientific rigor with operational flexibility to meet the diverse needs of pharmaceutical and biotechnology clients worldwide.

• Extensive experience with syngeneic bladder cancer models including MBT-2, MB49, and AY-27, ensuring model selection optimized to your therapeutic mechanism.
• Comprehensive in-house capabilities spanning tumor establishment, imaging, treatment administration, and multi-omic endpoint analysis under one roof.
• Rigorous quality management system with full traceability of cells, animals, and reagents, supported by comprehensive study documentation for regulatory submissions.
• Flexible study designs accommodating subcutaneous, orthotopic, and metastatic model configurations with customizable endpoints and readouts.
• Dedicated project management ensuring transparent communication, milestone tracking, and timely delivery of high-quality data packages.
• Competitive timelines and cost structures designed to accelerate your preclinical development pipeline without compromising scientific standards.

Contact Us

Ready to advance your bladder cancer therapeutic program with a validated MBT-2 xenograft model? Contact us today to discuss your study requirements, review our capabilities presentation, and receive a customized proposal tailored to your preclinical objectives. Please reach out to us today via our inquiry form or email to learn more about our MBT-2 Xenograft Model services.

For research use only. Not intended for any clinical use.